There are some skin conditions we're very familiar with: spots during adolescence, allergic rashes, sunburn. But others are ...

Phymatous rosacea: The skin thickens and becomes bumpy, particularly on the nose, which may cause it to enlarge. Ocular rosacea: The eyes and eyelids sting and become inflamed, watery, and bloodshot.

Patients with rosacea and skin of color are more likely to have severe disease phenotypes when compared with White patients with rosacea.

and ocular manifestations. Among the more recently approved treatments for rosacea — and among products and drug indications under study — “notice there’s a paucity of antibiotics ...

Continued to advance a robust pipeline. Pursuing the next potentially transformative category in eye care – Ocular Rosacea a highly prevalent and underserved eye disease with no FDA-approved ...

Earlier in this quarter, we introduced the next potentially transformer category in eye care, Ocular Rosacea. Much like DB, ocular rosacea is a chronic progressive disease caused by mite.

Eye irritation, dryness, redness, and burning may occur with ocular rosacea. Rosacea symptoms can vary in intensity and may come and go in cycles. Treating rosacea often requires a combination of ...

A Phase II study for ocular rosacea is set to begin in late 2025, with data expected in 2026. Tarsus aims to expand physician education to identify Demodex blepharitis in broader patient categories.

Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential ...

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) is advancing its pipeline with a phase 2 trial for ocular rosacea and a Lyme disease prevention program, indicating strong future growth potential.